Altria
MO
$73.72
+0.86%
Altria Group, Inc. is a leading tobacco company in the United States, operating primarily in the Consumer Defensive sector through its ownership of Philip Morris USA, U.S. Smokeless Tobacco, John Middleton, and its investments in reduced-risk products like vaping and heated tobacco. The company is a dominant market leader, holding the top position in U.S. cigarettes and smokeless tobacco, with its Marlboro brand commanding a 40% market share. The current investor narrative revolves around the company's high-yield dividend appeal and its ongoing, challenging transition into smoke-free products, as it contends with secular declines in its core cigarette business while investing in alternatives like NJOY and nicotine pouches to secure its long-term future.…
MO
Altria
$73.72
Related headlines
MO 12-Month Price Forecast
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Altria's 12-month outlook, with a consensus price target around $95.84 and implied upside of +30.0% versus the current price.
Average Target
$95.84
6 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
6
covering this stock
Price Range
$59 - $96
Analyst target range
Analyst coverage is limited, with only 6 analysts providing estimates, which is typical for a large, mature company in a niche industry. The consensus sentiment appears mixed, as recent institutional ratings include a 'Buy' from UBS and Stifel, an 'Underweight' from Barclays, and a 'Neutral' from Citigroup, indicating a lack of uniform conviction. The average revenue estimate for the upcoming period is $21.14 billion, with a low of $20.68 billion and a high of $21.41 billion, representing a tight range that suggests analysts have a high degree of certainty about near-term top-line performance, but the limited number of covering analysts means the consensus may not fully capture broader market sentiment.
Bulls vs Bears: MO Investment Factors
The evidence presents a classic battle between a high-yielding, cash-generative value stock and a company facing existential secular headwinds. The bull case is currently stronger, anchored by the undeniable appeal of a 7.2% yield backed by $9.07 billion in annual free cash flow and a dominant market position that ensures that cash flow's near-term stability. However, the single most important tension in the investment debate is the resolution of Altria's transition into smoke-free products. The bear case hinges on the failure of this transition, which would render the company's high leverage and declining core business unsustainable over the long term. The stock's recent rally to near its 52-week high suggests the market is giving some credit to the transition narrative, but the mixed analyst sentiment reflects deep-seated skepticism.
Bullish
- Strong Dividend Yield & Cash Flow: The stock offers a compelling 7.2% dividend yield, which is exceptionally high for an S&P 500 constituent. This is supported by robust free cash flow generation of $9.07 billion TTM, providing a high degree of safety for the payout.
- Dominant Market Position: Altria's Marlboro brand commands a 40% share of the U.S. cigarette market, providing a stable, high-margin cash cow. This entrenched leadership underpins the company's financial resilience despite secular volume declines.
- Attractive Valuation Multiples: The stock trades at a trailing P/E of 13.9x and a forward P/E of 12.5x, which is near the midpoint of its own historical range (5.2x to 21x). This suggests the stock is not overpriced relative to its earnings power and long-term risk profile.
- Recent Powerful Price Momentum: The stock has significantly outperformed the market, with a 1-month gain of +13.46% versus the S&P 500's +5.6%, and a 6-month gain of +25.61% versus the market's +10.01%. This strong relative strength indicates renewed investor interest, potentially driven by its defensive and high-yield characteristics.
Bearish
- Severe Financial Leverage: The company's balance sheet is highly leveraged, with a debt-to-equity ratio of -7.34 and a weak current ratio of 0.61. This significant debt burden limits financial flexibility and increases risk in a rising interest rate environment.
- Core Business Secular Decline: Altria's fundamental investment thesis is challenged by the long-term, structural decline in cigarette consumption. The company's future depends on successfully transitioning its revenue base to smoke-free products, a process that remains uncertain and capital-intensive.
- Volatile & Compressing Margins: While the TTM net margin is a healthy 34.5%, recent quarterly gross margins have shown significant compression, dropping to 62.1% in Q4 2025 from levels above 72% earlier in the year. This indicates potential cost pressures or an unfavorable sales mix shift.
- Limited Analyst Conviction: Analyst sentiment is mixed, with recent ratings including Buy, Neutral, and Underweight. Furthermore, coverage is limited to only 6 analysts, suggesting the stock may not be on the radar of the broader investment community, potentially limiting upside catalyst recognition.
MO Technical Analysis
The stock is in a sustained uptrend, evidenced by a 1-year price change of +25.89% and a 6-month gain of +25.61%. As of the latest close at $73.09, the price is trading at approximately 98% of its 52-week high of $74.56, indicating strong momentum but also positioning it near a critical resistance level where further gains may be difficult without a catalyst. Recent momentum has been exceptionally strong, with a 1-month surge of +13.46% and a 3-month gain of +8.68%, significantly outpacing the broader market's 1-month return of +5.6% as shown by its relative strength of +7.86, suggesting the stock is in a powerful short-term acceleration phase. Key technical levels are clearly defined, with immediate resistance at the 52-week high of $74.56 and support near the 52-week low of $54.70; a decisive breakout above resistance could signal a new leg higher, while a failure could lead to a consolidation. The stock's beta of 0.519 indicates it is roughly half as volatile as the broader market, which is typical for a defensive consumer staple, but the recent sharp price moves highlight that even low-beta stocks can experience significant directional moves.
Beta
0.52
0.52x market volatility
Max Drawdown
-19.1%
Largest decline past year
52-Week Range
$55-$75
Price range past year
Annual Return
+25.2%
Cumulative gain past year
| Period | MO Return | S&P 500 |
|---|---|---|
| 1m | +14.9% | +4.0% |
| 3m | +10.8% | +8.2% |
| 6m | +25.8% | +11.5% |
| 1y | +25.2% | +24.3% |
| ytd | +28.6% | +8.3% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
MO Fundamental Analysis
Revenue growth is modest but positive, with Q4 2025 revenue of $5.85 billion representing a year-over-year increase of 14.5%; however, this growth appears lumpy, as sequential quarterly revenue has fluctuated between $4.52 billion and $5.85 billion over the past year, indicating underlying business volatility rather than steady expansion. The company remains highly profitable, with Q4 2025 net income of $1.12 billion and a robust gross margin of 62.1%, though this margin has compressed from levels above 72% seen in prior quarters of 2025, suggesting potential cost pressures or mix shifts. Profitability metrics are strong on an operating basis, with an operating margin of 28.2% for the quarter, but the trailing twelve-month net margin stands at a healthy 34.5%, showcasing the firm's ability to convert sales to bottom-line earnings. The balance sheet and cash flow picture is mixed; the company generates substantial free cash flow, with TTM FCF of $9.07 billion, supporting its generous dividend, but it carries significant financial leverage as indicated by a negative debt-to-equity ratio of -7.34 and a weak current ratio of 0.61, which points to high debt levels and potential short-term liquidity constraints that are common in leveraged, cash-generative firms.
Quarterly Revenue
$5.8B
2025-12
Revenue YoY Growth
+0.14%
YoY Comparison
Gross Margin
+0.62%
Latest Quarter
Free Cash Flow
$9.1B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is MO Overvalued?
Given the positive net income, the primary valuation metric is the Price-to-Earnings (PE) ratio. The trailing PE is 13.92x, while the forward PE is lower at 12.46x, indicating the market expects modest earnings growth in the coming year. Compared to sector averages, Altria's trailing PE of 13.9x trades at a discount to the broader market but is in line with its own historical range for a tobacco company with limited growth prospects, though specific industry average data is not provided for a precise premium/discount calculation. Historically, the stock's own PE ratio has fluctuated significantly, from a low near 5.2x in mid-2024 to highs above 21x; the current level of 13.9x sits near the midpoint of this wide range, suggesting the market is pricing in a balanced view of its stable cash flows against long-term secular decline risks, without excessive optimism or pessimism.
PE
13.9x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range -8x~81x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
10.9x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks center on Altria's highly leveraged capital structure. With a debt-to-equity ratio of -7.34 and a current ratio of 0.61, the company has limited liquidity and significant interest expense obligations, consuming $264 million in the last quarter alone. Furthermore, revenue and margins exhibit high quarterly volatility; Q4 2025 revenue grew 14.5% YoY but gross margin compressed sharply to 62.1% from over 72%, indicating underlying business instability beyond the steady cash flow narrative. This volatility, combined with a payout ratio exceeding 100%, raises questions about the long-term sustainability of the dividend if earnings deteriorate.
Market & Competitive Risks are dominated by the secular decline of the core cigarette business and the uncertain payoff from investments in reduced-risk products like NJOY and nicotine pouches. The stock's low beta of 0.519 offers defensive characteristics, but its valuation is not immune to compression. Trading at a forward P/E of 12.5x, it is not excessively priced, but any acceleration in cigarette volume decline or regulatory setbacks for smoke-free alternatives could lead to a derating. The recent news highlights that 'smoke-free struggles remain a key risk,' underscoring the market's focus on this transition as the primary determinant of long-term value.
The Worst-Case Scenario involves a 'perfect storm' where cigarette volume declines accelerate faster than modeled, smoke-free product investments fail to gain meaningful traction, and rising interest rates exacerbate the high debt load. This could trigger a dividend cut, a severe loss of investor confidence, and a rapid valuation derating. The realistic downside from the current price of $73.09 is approximately -25% to the 52-week low of $54.70. A more severe bear case, incorporating multiple compression and earnings disappointment, could see the stock test levels 30-35% below current prices, mirroring the -19.15% max drawdown observed in the provided data.
